Heather Lau, MD, MS

Articles by Heather Lau, MD, MS

Heather Lau, MD, MS, on Using Heparan Sulphate as a Biomarker in the Clinical Study of MPSIIIA Gene Therapy UX111

February 17th 2024

The executive director of global clinical development at Ultragenyx Pharmaceutical discussed the statistical findings she presented at the 2024 WORLDSymposium.

Heather Lau, MD, MS, on Addressing Unmet Needs in MPSIIIA With Gene Therapy

ByHeather Lau, MD, MS

February 12th 2024

The executive director of global clinical development at Ultragenyx Pharmaceutical discussed UX111, the company’s investigational gene therapy for MPSIIIA.

Heather Lau, MD, MS

Articles by Heather Lau, MD, MS

Heather Lau, MD, MS, on Using Heparan Sulphate as a Biomarker in the Clinical Study of MPSIIIA Gene Therapy UX111

Heather Lau, MD, MS, on Addressing Unmet Needs in MPSIIIA With Gene Therapy

Latest Updated Articles

Trending on CGTlive®

Around the Helix: Cell and Gene Therapy Company Updates – November 5, 2025

What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy?

Guess the Therapy Answer November 5, 2025